T cell response by immune system is one step of the cancer-immunity cycle, critically responsible for maintenance of preventing autoimmunity. The possession of PD-L1 – a T cell inhibitory signal by cancer cells – have been identified for the development of new immunotherapy that are specifically responsible for hindering immune effector inhibition, thereby reinvigorating, and enhancing preexisting anticancer immune response. Previous activity in immune therapies has always considered suppressive factors in the tumor microenvironment without consideration to other factors such as the genetic and epigenetic basis of the immune system. Attention to the immune system has always been on the response to the pathogens, but not on the genes responsible for regulating the immune system, and the cellular communication within the microenvironment.